This is an open-label Phase 1a/b dose-escalation study to assess the safety, tolerability, and PK of OMP-131R10 as a single agent for advanced solid tumors and in subjects with metastatic colorectal cancer.
A Phase 1a/b Dose Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of OMP-131R10 in Advanced Solid Tumors and in Combination With FOLFIRI for Patients With Previously Treated Metastatic Colorectal Cancer
The Phase 1a portion of the study in subjects with advanced solid tumors will consist of a dose escalation part followed by a dose-expansion cohort. OMP-131R10 will be administered IV on the first day of each 14-day cycle.
Dose escalation will follow a traditional 3+3 framework. Treatment will be continued until progressive disease or unacceptable toxicity.
The Phase 1b portion of the study will be conducted in subjects with metastatic colorectal cancer whose tumors have progressed after at least 1 line of therapy for metastatic disease.
Treatment will consist of OMP-131R10 and the FOLFIRI chemotherapy regimen.
Advanced Relapsed TumorsRefractory Solid TumorsAdvanced Solid Tumors and in CombinationFOLFIRI for Patients with Previously Treated MetastaticColorectal Cancer
You can join if…
Open to people ages 18 years and up
Subjects must meet all of the following criteria to be eligible for the study:
Phase 1a portion: Histologically confirmed advanced relapsed or refractory solid tumors that have exhausted standard of care therapy or either refuse or are not considered to be candidates for any remaining standard therapy.
Age ≥18 years
ECOG performance status 0 or 1 (see Appendix B)
Must have evaluable disease per RECIST 1.1. (see Appendix C)
Subjects must have Formalin-Fixed, Paraffin-Embedded (FFPE) tissue available either archived or fresh core or punch needle biopsied at study entry (two fresh cores/punches preferred whenever possible).
Must have received their last anti-cancer therapy, including radiotherapy,chemotherapy, biologic therapy, or herbal therapy at least 3 weeks or 5 half-lives(for systemic agents), whichever is shorter, from initiation of study treatment.
Platelets>100,000/mL without transfusions in the past 7 days
Total bilirubin within 1.5x institutional upper limit of normal (ULN)
AST (SGOT) and ALT (SGPT) <3 X institutional ULN
Patients with documented liver metastases: AST (SGOT) and/or ALT (SGPT) ≤ 5 ×ULN
Albumin ≥ 3.0 g/dL
Creatinine <1.5 X institutional ULN OR
Creatinine clearance>50 mL/min/1.73 m2 for subjects with creatinine levels above institutional normal
You CAN'T join if...
Subjects who meet any of the following criteria will not be eligible for participation in the study:
Currently receiving any therapeutic treatment for their malignancy including other investigational agents
Uncontrolled seizure disorder, active neurologic disease, or active CNS involvement except for individuals who have previously treated CNS metastases, are asymptomatic,and have no requirement for a corticosteroid dose (indicated to reduce brain edema)that is equivalent to a prednisone dose of>10mg orally per day or anti-seizure medication for at least 4 weeks prior to first dose of study drug.
History of a Grade 3 or 4 allergic reaction attributed to humanized or human monoclonal antibody therapy
Significant intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
Pregnant women or nursing women
Subjects with congestive heart failure with New York Heart Association Classification III, or IV (see Appendix D)
Known clinically significant gastrointestinal disease including, but not limited to,inflammatory bowel disease
UCSFaccepting new patients San Francisco, California, 95115, United States
University of Colorado Hospital Anschulz Cancer Pavilionaccepting new patients Aurora, Colorado, 80045, United States
M.D. Anderson Cancer Centeraccepting new patients Houston, Texas, 77030, United States
The Sarah Cannon Research Instituteaccepting new patients Nashville, Tennessee, 37203, United States
Duke Universityaccepting new patients Durham, North Carolina, 27710, United States
Yaleaccepting new patients New Haven, Connecticut, 06520-8028, United States